OMER - Omeros price target raised at BofA on expert views for narsoplimab

Maintaining their buy rating, the analysts at Bank of America have upgraded the price target of Omeros Corporation ([[OMER]] +1.2%) citing expert views on the potential of the company’s experimental monoclonal antibody narsoplimab for transplant-associated thrombotic microangiopathy.Noting the significant effect of the MASP-2 inhibitor in terms of higher response rates and survival durations, the KOL, Dr. Nelson Chao, a Professor of Medicine, and Immunology at Duke University, was ‘very positive’ on narsoplimab, the analyst Geoff Meacham and the team wrote.The expert predicts a potential approval for the therapy and subsequent uptake by physicians despite some requirement of creating awareness.In January, Omeros announced that the FDA has accepted its Biologics License Application for Narsoplimab in transplant-associated thrombotic microangiopathy with a target action date of July 17.

For further details see:

Omeros price target raised at BofA on expert views for narsoplimab